Similar articles

• Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.

  Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G. Weycker D, et al. Am J Clin Oncol. 2012 Jun;35(3):267-74. doi: 10.1097/COC.0b013e31820dc075. Am J Clin Oncol. 2012. PMID: 21378538
• Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

  Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS. Heaney ML, et al. Cancer. 2009 Oct 15;115(20):4839-48. doi: 10.1002/cncr.24535. Cancer. 2009. PMID: 19637341
• Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.

  Stull DM, Bilmes R, Kim H, Fichtl R. Stull DM, et al. Am J Health Syst Pharm. 2005 Jan 1;62(1):83-7. doi: 10.1093/ajhp/62.1.83. Am J Health Syst Pharm. 2005. PMID: 15658078 Clinical Trial. No abstract available.
• Clinical applications of colony-stimulating factors: a historical perspective.

  Sylvester RK. Sylvester RK. Am J Health Syst Pharm. 2002 Apr 1;59(7 Suppl 2):S6-12. doi: 10.1093/ajhp/59.suppl_2.S6. Am J Health Syst Pharm. 2002. PMID: 11944613 Review.
• Myeloid growth factors.

  Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK; National Comprehensive Cancer Network. Crawford J, et al. J Natl Compr Canc Netw. 2009 Jan;7(1):64-83. doi: 10.6004/jnccn.2009.0006. J Natl Compr Canc Netw. 2009. PMID: 19176207 No abstract available.